N/A

Loading page data
Please wait a moment
Second Floor, 150 Fleet Street,
London, EC4A 2DQ.
+44 203-837-5656
108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018
+1 646-878-6329
IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.
+91 906 779 3500





Chymotrypsin test is done to check the pancreatic functioning, this test help to identify the Pancreatic Insufficiency towards the production of digestive enzymes. Chymotrypsin is an enzyme which is responsible for the digestion of proteins in a small intestine. Chymotrypsin test measures the amount of chymotrypsin in the stool that helps to identify the pancreas functioning.
Chymotrypsin test is normally used along with another test such as fecal fat test, urine test, etc. Chymotrypsin test is done to diagnose acute or chronic pancreatic disorders. It is frequently associated with pancreatic disorders. In children, chymotrypsin test is done to diagnose the cystic fibrosis (CF) or Shwachman-Diamond Syndrome (SDS).
Chymotrypsin test is done on the stool sample within a 72 hour period for getting the proper results. Chymotrypsin test is based on the ELISA test principle, which identifies the chymotrypsin enzyme in the stool. In chymotrypsin test market, kits are available in 48-Strip-Wells, 96-Strip-Wells.
Rising patient pool suffering from the acute and chronic pancreatic disorders may drive the chymotrypsin test market. People suffering from the disorders like indigestion, gastroesophageal reflux disease (GERD) may show the fueling growth for chymotrypsin test market.
Disease conditions like persistent diarrhea, vitamin deficiency, malnutrition will show the additional demand of the chymotrypsin test market. In children cystic fibrosis (CF) or Shwachman-Diamond Syndrome (SDS) diagnosis may show the propelling growth for chymotrypsin test market.
Alternative diagnosis methods like CT scan, Endoscopy for the pancreatic testing may show the slower growth for chymotrypsin test market. Awareness of the people about the cystic fibrosis and pancreatic cancer may show the stagnancy in the chymotrypsin test market.